Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.77 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.77 |
| ▸ | HTR5A | P47898 | 1/20 | 0.77 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.77 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.74 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736160 | 1.00 | HTR2A (1.00) | HTR2AHTR2CKDM4ENR2E1HTR5A | |
| SCHEMBL11845764 | 0.90 | HTR2A (0.81) | HTR2AHTR2CKDM4ENR2E1HTR5A | |
| SCHEMBL11839582 | 0.88 | HTR2A (0.78) | HTR2AHTR2CKDM4ENR2E1HTR5A | |
| Tryptoline SCHEMBL28477910 | 0.87 | NISCH (0.93) | HTR2AHTR2CKDM4ENR2E1HTR5A | |
| Tryptoline SCHEMBL171755 | 0.87 | NISCH (1.00) | HTR2AHTR2CKDM4ENR2E1HTR5A | |
| Tryptoline SCHEMBL29350043 | 0.87 | NISCH (1.00) | HTR2AHTR2CKDM4ENR2E1HTR5A | |
| Tryptoline SCHEMBL12190178 | 0.87 | NISCH (1.00) | HTR2AHTR2CKDM4ENR2E1HTR5A | |
| Tryptoline SCHEMBL9754749 | 0.87 | NISCH (1.00) | HTR2AHTR2CKDM4ENR2E1HTR5A | |
| Tryptoline SCHEMBL9480983 | 0.87 | NISCH (1.00) | HTR2AHTR2CKDM4ENR2E1HTR5A | |
| SCHEMBL169954 | 0.87 | TAAR1 (0.96) | HTR2AHTR2CKDM4ENR2E1HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61263978-A | — | — | None | — | — | JP | disclosed |
| US-20260138985-A1 | Azepino-Indoles for the Treatment of Neurological and Psychiatric Disorders | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250235463-A1 | PHENOXY AND BENZYLOXY SUBSTITUTED PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-12295959-B2 | Phenoxy and benzyloxy substituted psychoplastogens and uses thereof | DELIX THERAPEUTICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4448531-A1 | PHENOXY AND BENZYLOXY SUBSTITUTED PSYCHOPLASTOGENS AND USES THEREOF | Delix Therapeutics, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448532-A1 | FUSED PYRROLIDINE PSYCHOPLASTOGENS AND USES THEREOF | Delix Therapeutics, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4288048-A1 | OXA-IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | The Trustees Of Columbia University In The City Of New York (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023114313-A1 | PHENOXY AND BENZYLOXY SUBSTITUTED PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114320-A1 | FUSED PYRROLIDINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114320-A1 | FUSED PYRROLIDINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-5616575-A | COCAINE ADDICTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1997-04-01 | — | — | US | disclosed |
| EP-0466548-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indole and 1,2,3,4-tetrahydro-beta-carbolines, processes for their preparation, and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-01-15 | — | — | EP | disclosed |
| EP-0203902-A3 | 1,2,3,4,5,6-Hexahydro-azepino[4,5-b] indole derivatives, their preparation, intermediate compounds and their therapeutical use | OMNICHEM Société anonyme (BE) | 1988-05-18 | — | — | EP | disclosed |
| US-4719208-A | 1,2,3,4,5,6-hexahydroazepino(4,5-B)indole derivatives, their preparation, intermediate compounds, and their application in therapeutics | OMNICHEM SOCIETE ANONYME (BE) | 1988-01-12 | — | — | US | disclosed |
| US-4719208-A | 1,2,3,4,5,6-hexahydroazepino(4,5-B)indole derivatives, their preparation, intermediate compounds, and their application in therapeutics | OMNICHEM SOCIETE ANONYME (BE) | 1988-01-12 | — | — | US | disclosed |
| EP-0203902-A2 | 1,2,3,4,5,6-Hexahydro-azepino[4,5-b] indole derivatives, their preparation, intermediate compounds and their therapeutical use | OMNICHEM Société anonyme (BE) | 1986-12-03 | — | — | EP | disclosed |
| JP-S61263978-A | 1,2,3,4,5,6-HEXAHYDROAZEPINO(4,5-B) INDOLE DERIVATIVE, ITS PRODUCTION,INTERMEDIATE COMPOUND AND APPLICATION THEREOF IN TREATMENT | OMNICHEM SA | 1986-11-21 | — | — | JP | disclosed |
| EP-0028381-B1 | AZEPINOINDOLES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANDOZ AG (CH) | 1985-04-10 | — | — | EP | disclosed |
| EP-0011057-A1 | Process for the preparation of vincadifformine and derivatives thereof, intermediates obtained during this process and process for their preparation | OMNICHEM Société anonyme (BE) | 1980-05-14 | — | — | EP | disclosed |
| US-3839357-A | 1,2,3,4,5,6-HEXAHYDROAZEPINO(4,5-B)INDOLES | UPJOHN CO | 1974-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138985-A1 | Azepino-Indoles for the Treatment of Neurological and Psychiatric Disorders | TPH2, TPH1, HTR1D | HTR2A 5/4885HTR2C 4/4885KDM4E 283/4885 |
| US-12295959-B2 | Phenoxy and benzyloxy substituted psychoplastogens and uses thereof | GAP43, BDNF, GRIN2A | HTR2A 80/4885HTR2C 88/4885KDM4E 1289/4885 |
| US-20250235463-A1 | PHENOXY AND BENZYLOXY SUBSTITUTED PSYCHOPLASTOGENS AND USES THEREOF | GAP43, BDNF, GRIN2A | HTR2A 80/4885HTR2C 88/4885KDM4E 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.